On February 20, 2018 Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, reported that the Company’s scientists, and collaborators from the Mount Sinai School of Medicine, will present two abstracts at the American Chemical Society National Meeting & Expo (Press release, Onconova, FEB 20, 2018, View Source [SID1234524076]). The meeting is being held in New Orleans, LA, on March 18-22, 2018.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The first abstract relates to the analysis of stability of the clinical product during storage and describes the synthesis and characterization of a de-sulfonylated product of rigosertib, Onconova’s lead phase 3 stage clinical candidate. The second abstract describes a new chemical entity ON 150030, which is a type 1 novel pre-clinical stage inhibitor of FLT3 and Src pathways, believed to be important for targeted therapy of relapsed and refractory AML.
Details for the poster presentations are listed below.
Title: Synthesis and characterization of de-sulfonylated product of rigosertib, a late phase III clinical candidate
Date: 18th March, 2018
Presentation Time: 7.00-9.00 PM CDT
Presenter: Dr. M.V. Ramana Reddy & Dr. Muralidhar Mallireddigari
Location: Ernest N. Morial Convention Center, Hall E.
Title: Discovery of a novel kinase inhibitor ON 150030, a type 1 inhibitor for relapsed and refractory AML
Date: 18th March, 2018
Presentation Time: 7.00-9.00 PM CDT
Presenter: Dr. M.V. Ramana Reddy
Location: Ernest N. Morial Convention Center, Hall E.